Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Relapse/Refractory myeloma patient: potential treatment guidelines.

San Miguel JF.

J Clin Oncol. 2009 Dec 1;27(34):5676-7. doi: 10.1200/JCO.2009.24.3683. Epub 2009 Sep 28. No abstract available.

PMID:
19786652
2.

Novel agents for relapsed and/or refractory multiple myeloma.

Thomas SK, Richards TA, Weber DM.

Cancer J. 2009 Nov-Dec;15(6):485-93. doi: 10.1097/PPO.0b013e3181c51cba. Review.

PMID:
20010168
3.

Treatment options for relapsed and refractory multiple myeloma.

Lonial S, Mitsiades CS, Richardson PG.

Clin Cancer Res. 2011 Mar 15;17(6):1264-77. doi: 10.1158/1078-0432.CCR-10-1805. Review.

4.

An update on drug combinations for treatment of myeloma.

Srikanth M, Davies FE, Morgan GJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):1-12. Review.

PMID:
18095914
5.

[Therapy of multiple myeloma: indications and options].

Peest D, Ganser A.

Internist (Berl). 2007 Dec;48(12):1343-8. Review. German.

PMID:
17960351
6.

[Multiple myeloma].

Iida S.

Rinsho Ketsueki. 2012 Feb;53(2):155-63. Review. Japanese. No abstract available.

PMID:
22450574
7.

Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?

Ludwig H, Sonneveld P.

Leuk Res. 2012 Nov;36 Suppl 1:S27-34. doi: 10.1016/S0145-2126(12)70006-1. Review.

PMID:
23176721
8.

[Prognostic factors and new treatments of multiple myeloma].

Leleu X, Coiteux V, Facon T.

Rev Prat. 2006 Jan 15;56(1):31-9. Review. French.

PMID:
16548247
9.

The role of novel drugs in multiple myeloma.

Dimopoulos MA, Kastritis E.

Ann Oncol. 2008 Sep;19 Suppl 7:vii121-7. doi: 10.1093/annonc/mdn444. Review. No abstract available.

PMID:
18790953
10.

Novel therapies in myeloma.

Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG.

Curr Opin Hematol. 2007 Nov;14(6):609-15. Review.

PMID:
17898564
11.

Treatment of multiple myeloma in the targeted therapy era.

Saad AA, Sharma M, Higa GM.

Ann Pharmacother. 2009 Feb;43(2):329-38. doi: 10.1345/aph.1L428. Epub 2009 Feb 3. Review.

PMID:
19193585
12.

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma.

Lonial S, Cavenagh J.

Br J Haematol. 2009 Jun;145(6):681-708. doi: 10.1111/j.1365-2141.2009.07649.x. Epub 2009 Mar 17. Review.

PMID:
19344388
13.

[Multiple myeloma--recent advances in diagnosis and treatment].

Chou T.

Gan To Kagaku Ryoho. 2005 Mar;32(3):304-8. Review. Japanese.

PMID:
15791813
14.

Treatment of relapsed and refractory myeloma.

Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, LeBlanc R, Belch AR, White D, Kovacs MJ.

Leuk Lymphoma. 2008 Aug;49(8):1470-85. doi: 10.1080/10428190802064941. Review.

PMID:
18608859
15.

Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature.

Méndez CE, Hwang BJ, Destian S, Mazumder A, Jagannath S, Vesole DH.

Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):220-3. doi: 10.3816/CLML.2010.n.035. Review.

PMID:
20511169
16.

Initial therapy in multiple myeloma: investigating the new treatment paradigm.

Kettle JK, Finkbiner KL, Klenke SE, Baker RD, Henry DW, Williams CB.

J Oncol Pharm Pract. 2009 Sep;15(3):131-41. doi: 10.1177/1078155208101096. Epub 2009 Mar 10. Review.

PMID:
19276138
17.

[Treatment for multiple myeloma: current status and future strategy in Japan].

Iida S.

Rinsho Ketsueki. 2008 Oct;49(10):1368-73. Review. Japanese. No abstract available.

PMID:
18833921
18.

[Recent progress in the treatment of multiple myeloma].

Iida S.

Rinsho Ketsueki. 2007 Feb;48(2):91-9. Review. Japanese. No abstract available.

PMID:
17370637
19.

Multiple myeloma: charging toward a bright future.

Katzel JA, Hari P, Vesole DH.

CA Cancer J Clin. 2007 Sep-Oct;57(5):301-18. Review.

20.

Bortezomib in combination with other therapies for the treatment of multiple myeloma.

Orlowski RZ.

J Natl Compr Canc Netw. 2004 Nov;2 Suppl 4:S16-20. Review.

PMID:
19791424

Supplemental Content

Support Center